HIRO-CAPITAL
3.1.2022 15:17:11 CET | Business Wire | Press release
Today, Hiro Capital is proud to announce that its co-founding Partner, Ian Livingstone has been granted the title of Knight Bachelor by HRH Queen Elizabeth II. Sir Ian is best known as one of the founders of Games Workshop (Warhammer) and Eidos (Lara Croft Tomb Raider) and as the creator of the Fighting Fantasy series of adventure game novels. Over the course of his legendary career, Sir Ian has made innumerable contributions to the art and industry of video and role-playing games. Three of Ian’s recent investments - Tonic Games (Fall Guys), Playdemic (Golfclash), and Sumo Digital - were acquired in 2021 at unicorn valuations and Hiro Capital has made 20 early-stage games investments in the last 2 years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005197/en/
“With 5 unicorn scale games start-ups under his knightly belt, Hiro Capital is proud to celebrate Sir Ian’s knighthood. His bravery, chivalry, courtliness, and hermetical talents make him one of the most powerful paladins in video games. We are proud to have Sir Ian co-leading the Hiro Capital guild of mages and sell-swords as we ride forward into the Metaverse of 2022,” said Luke Alvarez and Cherry Freeman, Hiro co-founders.
“Simply put, it is a huge honor for me and great recognition for the UK games industry. The industry has come a long way since I founded my first startup and I believe more than ever in Games and Gameplay as a global force for good.” - said Sir Ian Livingstone.
Ian also recently founded the Livingstone Academy, which opened its doors in September - an all-through school for ages four to eighteen that aims to give its students the tools they need to succeed as young creators in a digital world. Find out more - https://www.livingstone-aspirations.org/
Hiro Capital: Investors in the Future
Hiro Capital is a London / Luxembourg technology Venture Capital fund which invests in UK, US, and European innovators in Games, IP, Metaverse Technology, Web 3.0, Esports, and Gamified Fitness. Hiro Capital generally invests at Seed through Series A and B stages. We invest both in front-end Content creators in Games, IP, Esports, and Digital Fitness and in deep tech Metaverse and Web 3.0 applications of Cloud, Mobile, Streaming, Creator Tools, Big Data, AI, Wearables, AR, and VR. - https://hiro.capital/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005197/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom